What is HC Wainwright’s Forecast for ATRA FY2024 Earnings?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Atara Biotherapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst R. Burns anticipates that the biotechnology company will post earnings per share of ($11.46) for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($9.86) per share. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q4 2024 earnings at ($5.20) EPS, Q1 2025 earnings at ($4.35) EPS, Q2 2025 earnings at ($4.15) EPS, Q3 2025 earnings at $3.35 EPS, Q4 2025 earnings at ($3.90) EPS and FY2025 earnings at ($9.08) EPS.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same period last year, the firm posted ($16.50) earnings per share.

Other research analysts also recently issued research reports about the company. Rodman & Renshaw started coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They set a “buy” rating and a $25.00 price target for the company. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. Canaccord Genuity Group lowered their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, January 17th. Finally, RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Atara Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Atara Biotherapeutics Stock Up 18.6 %

ATRA opened at $8.22 on Friday. Atara Biotherapeutics has a twelve month low of $5.40 and a twelve month high of $39.50. The company’s 50-day moving average price is $11.97 and its two-hundred day moving average price is $9.96. The stock has a market cap of $47.35 million, a price-to-earnings ratio of -0.32 and a beta of 0.51.

Institutional Trading of Atara Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at $53,000. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics during the second quarter valued at $79,000. State Street Corp grew its position in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after buying an additional 7,680 shares in the last quarter. FMR LLC grew its position in Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 4,043 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.